Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Haemonetics Corp (NY: HAE )

81.16 -2.30 (-2.76%)
Streaming Delayed Price Updated: 3:43 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Haemonetics Corp

< Previous 1 2 3 4 Next >
For those who appreciate growth without the sticker shock, NYSE:HAE is worth considering.
For those who appreciate growth without the sticker shock, NYSE:HAE is worth considering. 
Via Chartmill
Earnings Scheduled For February 8, 2024
Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share on revenue of $864.54 million. 
Via Benzinga
Intuitive Surgical Stock Earns Relative Strength Rating Upgrade; Hits Key Benchmark
Intuitive Surgical stock saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an increase from 74 to 85. 
Via Investor's Business Daily
Intuitive Surgical Stock Rating Climbs As Sales, Profits Rise
Intuitive Surgical stock got an IBD rating upgrade Monday. It edged up 0.37% to 274.16, its second day in a row of rising share price. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Is HAEMONETICS CORP/MASS (NYSE:HAE) suited for quality investing?
Why the quality investor may take a look at HAEMONETICS CORP/MASS (NYSE:HAE). 
Via Chartmill
Exploring NYSE:HAE's quality characteristics.
Should you consider HAEMONETICS CORP/MASS (NYSE:HAE) for quality investing? 
Via Chartmill
Should you consider NYSE:HAE for quality investing?
HAEMONETICS CORP/MASS (NYSE:HAE) may be suited for quality investing, we'll explore why in this article. 
Via Chartmill
4 Analysts Have This to Say About Haemonetics
Via Benzinga
Intuitive Surgical Stock Nearly Doubles; Gets Rating Upgrade
Intuitive Surgical stock dipped to an intraday low 180.07 in October last year as the bear market ended, then shot up to 358.07 on July 19. 
Via Investor's Business Daily
Haemonetics Earnings Preview
Via Benzinga
Haemonetics Corp. (NYSE: HAE) Making Surprising Moves in Monday Session
Via Investor Brand Network
Haemonetics Q4 Earnings Exceed Expectations On Volume And Price Benefits
Via Benzinga
Recap: Haemonetics Q4 Earnings
Via Benzinga
Looking Into Haemonetics's Return On Capital Employed
Via Benzinga
Alphabet To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Wednesday
Loop Capital boosted the price target for Alphabet Inc. (NASDAQ: GOOGL) from $120 to $125. Loop Capital analyst Rob Sanderson maintained a Buy rating. Alphabet shares fell 3.7% to $103.70 in pre-market... 
Via Benzinga
Earnings Preview: Haemonetics
Via Benzinga
Where Haemonetics Stands With Analysts
Via Benzinga
9 Analysts Have This to Say About Haemonetics
Via Benzinga
Incyte, Haemonetics Post Earnings Beats; One Surges Within Buy Zone
Haemonetics stock rose within a buy zone on Tuesday, but Incyte stock toppled. 
Via Investor's Business Daily
How 2022's Biggest Healthcare Gainers Could Fare In 2023
Health care stocks were hit hard early in the pandemic but these three have made quite a comeback. This article examines where they could go in 2023 
Via MarketBeat
InMode Stock Shows Improved Technical Strength; Hits Key Technical Threshold
The Relative Strength (RS) Rating for InMode stock moved up into a higher percentile Wednesday, as it got a lift from 64 to 78. 
Via Investor's Business Daily
Analysts Take Bullish Stance On Haemonetics, Cites Plasma Momentum As Catalyst
Via Benzinga
Haemonetics: Q2 Earnings Insights
Haemonetics (NYSE:HAE) reported its Q2 earnings results on Monday, November 7, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Earnings Haemonetics beat estimated earnings... 
Via Benzinga
Expert Ratings for Haemonetics
Over the past 3 months, 6 analysts have published their opinion on Haemonetics (NYSE:HAE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's session, 108 stocks hit new 52-week highs. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022
Upgrades 
Via Benzinga
Leading Medical Stocks, Including Sensus And Shockwave, Have Grown At Least 36% This Year
Biotech isn't the only place to make money in health care this year. 
Via Investor's Business Daily
Cutera Stock Earns Relative Strength Rating Upgrade
On Monday, medical aesthetic Cutera stock had its Relative Strength (RS) Rating upgraded to 90 from 80 a day earlier. 
Via Investor's Business Daily
Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.